INHIBRX BIOSCIENCES, INC. Stock-Based Compensation
INHIBRX BIOSCIENCES, INC. (INBX) reported Stock-Based Compensation of $5.76 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-13
- INHIBRX BIOSCIENCES, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $3.10M, a 12.06% increase year-over-year.
- INHIBRX BIOSCIENCES, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $2.65M, a 8.29% increase year-over-year.
- INHIBRX BIOSCIENCES, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $2.74M, a 8.01% decline year-over-year.
- INHIBRX BIOSCIENCES, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $3.17M, a 7.08% increase year-over-year.
- INHIBRX BIOSCIENCES, INC. share-based payment arrangement, noncash expense for fiscal 2025 was $11.14M, a 80.97% decline from fiscal 2024.
- INHIBRX BIOSCIENCES, INC. share-based payment arrangement, noncash expense for fiscal 2024 was $58.52M, a 135.52% increase from fiscal 2023.
- INHIBRX BIOSCIENCES, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $24.85M.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $5.76M 10-Q · filed 2026-08-13 | $8.50M derived: sum of 3 quarters · filed 2026-08-13 | $11.68M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $2.65M 10-Q · filed 2026-05-14 | $5.40M derived: sum of 2 quarters · filed 2026-05-14 | $8.57M derived: sum of 3 quarters · filed 2026-05-14 | $11.34M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $2.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $5.92M derived: sum of 2 quarters · filed 2026-03-19 | $8.69M derived: sum of 3 quarters · filed 2026-08-13 | $11.14M 10-K · filed 2026-03-19 |
| 2025-09-30 | $3.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $5.95M derived: sum of 2 quarters · filed 2026-08-13 | $8.39M 10-Q · filed 2025-11-14 | $11.38M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $2.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $5.22M 10-Q · filed 2026-08-13 | $8.20M derived: sum of 3 quarters · filed 2026-08-13 | $11.17M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $2.45M 10-Q · filed 2026-05-14 | $5.43M derived: sum of 2 quarters · filed 2026-05-14 | $8.40M derived: sum of 3 quarters · filed 2026-05-14 | $54.57M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $2.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $5.95M derived: sum of 2 quarters · filed 2026-03-19 | $52.12M derived: sum of 3 quarters · filed 2026-03-19 | $58.52M 10-K · filed 2026-03-19 |
| 2024-09-30 | $2.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $49.14M derived: sum of 2 quarters · filed 2025-11-14 | $55.54M 10-Q · filed 2025-11-14 | $61.96M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $46.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $52.57M 10-Q · filed 2025-08-13 | $59.00M derived: sum of 3 quarters · filed 2025-08-13 | $65.53M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $6.40M 10-Q · filed 2025-05-14 | $12.82M derived: sum of 2 quarters · filed 2025-05-14 | $19.35M derived: sum of 3 quarters · filed 2025-05-14 | |
| 2023-12-31 | $6.43M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $12.96M derived: sum of 2 quarters · filed 2025-03-17 | $24.85M 10-K · filed 2025-03-17 | |
| 2023-09-30 | $6.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $18.42M 10-Q · filed 2024-11-14 | ||
| 2023-06-30 | $11.89M 10-Q · filed 2024-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |